Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “3.33 μg/kg, 8.33 μg/kg, or 16.67 μg/kg of WSK-IM02 as monotherapy via intraperitoneal injection.”In the company’s words, NCT07462468 on ClinicalTrials.gov
- Tested for
- Platinum-resistant Recurrent Ovarian Cancer (PROC), Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
- Main trialPhase 1
- “A Phase 1, single-arm, single-center, open-label, prospective, dose-escalation, and cohort expansion study to assess the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of WSK-IM02 administered as a single agent to patients with platinum-resistant recurrent ovarian cancer.”In the company’s words, NCT07462468 on ClinicalTrials.gov
Other drugs for Platinum-resistant Recurrent Ovarian Cancer (PROC)
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up2
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Jan 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 31 Mar 2027 | A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. | |
| Phase 1Not yet recruiting | 30 Jan 2028 | WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026